Difficult access to capital, an uncertain regulatory environment, and lack of innovation and productivity in R&D are the biggest threats to growth in the US biomedical industry over the next five years, according to industry leaders asked for a survey of California Healthcare Institute, BayBio and PwC Us.
The 74% of US biomedical industry CEOs, for example, said they had to delay a research or development project over the past year. And lack of funds is the main reason cited. CEO's 44% also assures that it will seek licensing deals and partnerships as a source of funding over the next 12 months, twice as many as those who said the same thing last year.
Corporate venture financing is also set to become a preferred source of capital for the industry, with 30% of surveyed CEOs turning to this source over the next 12 months versus 10% last year.
The research also finds that, for the CEOs of biomedical companies, the FDA is also a problem: the 80% of respondents "agree or strongly agree" that the current drug approval process has slowed the growth of the their company.
Barbara Di Chiara – January 16, 2012 – PharmaKronos
